The use of high-dose chemotherapy for metastatic breast cancer has been an area of recent interest and the role of such treatment in the management of metastatic breast cancer is still to be defined. Multiple studies have suggested that such treatment can be given with minimal morbidity and mortality. We describe two cases of life-threatening interstitial pneumonitis, following highdose chemotherapy (HDT) with cyclophosphamide, thiotepa and docetaxel with stem cell rescue given for metastatic breast cancer. The available relevant literature is reviewed. Bone Marrow Transplantation (2001) 27, 559-563. Keywords: pneumonitis; cyclophosphamide; thiotepa; docetaxel Pulmonary complications are a major source of mortality and morbidity in regimens involving high-dose chemotherapy/chemoradiotherapy and autologous or allogeneic stem cell transplantation.
Pulmonary complications are a major source of mortality and morbidity in regimens involving high-dose chemotherapy/chemoradiotherapy and autologous or allogeneic stem cell transplantation. 1 Non-infectious pulmonary complications occur in 10-25% of bone marrow transplant recipients. After allogeneic transplantation, diffuse lung injury in the absence of an identifiable infection (also known as idiopathic pneumonia syndrome) occurs in 10 to 15% of patients. It has a median onset of 21 days post transplantation and is associated with a mortality rate of up to 75%. 2, 3 Pulmonary complications after autologous transplantation are more variable and have contributed to mortality seen in recent large randomised trials of high-dose therapy (HDT) in high-risk primary breast cancer. 4 Various conditioning regimens and prior radiotherapy have been implicated in the pathogenesis, particularly BCNU-containing regimens which have a reported incidence of 29 to 64%. 2 Here, we describe two cases of life-threatening pneumonitis following high-dose cyclophosphamide, docetaxel and thiotepa with stem cell rescue for the treatment of metastatic breast cancer. 
Case reports

Case 1
A previously well, 41-year-old female non-smoker was diagnosed with a T2N0M0 high-grade oestrogen receptorpositive infiltrating ductal cancer of the right breast. Following partial mastectomy and axillary dissection, she received six cycles of adjuvant CMFP (cyclophosphamide, methotrexate, 5-flurouracil, prednisolone). No chest wall irradiation was administered. Four years later she developed an isolated metastasis in her seventh thoracic vertebra which was treated with local radiotherapy (RT) (30 Gy in 10 fractions to T5 to T9) and tamoxifen. No acute lung toxicity was observed. Seventeen months later she developed a metastasis in the left eleventh rib. She received further local RT (8 Gy as a single fraction) and was commenced on anastrazole. However, within 1 month she progressed, with widespread metastatic bone disease and two small lung nodules within the right upper lobe.
At this time she entered a phase I/II clinical trial of repetitive HDT with PBPC support. 5 Prior to HDT she received two cycles of docetaxel (100 mg/m 2 ), the second followed by G-CSF (10 g/kg/day s.c.) for the mobilisation of PBPCs. 6 Subsequently, she received the first cycle of HDT consisting of cyclophosphamide (CTX) (4 g/m /kg peripheral blood progenitor cells (PBPC) were infused. On day 10 she developed fever, dyspnoea and a dry cough with a right upper lobe infiltrate on chest X-ray. A nasopharyngeal aspirate was positive for respiratory syncytial virus (RSV) and she responded to vancomycin, ceftazidime, erythromycin and nebulized ribavirin. She again clinically improved but remained neutropenic.
On day 21 her neutrophils were 0.06 × 10 9 /l and because of delayed recovery her 'back-up' PBPC were infused (0.68 × 10 6 /kg). Just prior to PBPC infusion she developed recurrent fever and dyspnoea, and a CXR demonstrated patchy bilateral changes. High-resolution chest CT (HRCT) showed patchy ground glass opacities, with patchy nodular changes (without cavitation) in both upper lobes (Figure 1 ). Intravenous amphotericin (1 mg/kg/day) was added to her antibiotic regimen. No fungus was identified in sputum culture. Her blood counts recovered on day 23 and she was discharged home.
Bone Marrow Transplantation On day 26 she developed recurrent dyspnoea and a 40°C fever associated with a generalised maculopapular rash predominantly on her face, nape of neck and upper torso ( Figure 2 ). At this time her neutrophil count had recovered to 8.8 × 10 9 /l. Meropenem, amphotericin, vancomycin and ribovirin and pre-emptive acyclovir and zoster immunoglobulin were commenced. Skin biopsy revealed urticarial vesiculo-bullous allergic reaction with no evidence of herpes infection. She continued to deteriorate over the next 48 h with progressive dyspnoea, hypoxia and rapidly progressive bilateral infiltrate on CXR. She required respiratory support with continuous positive airways pressure (CPAP). Bronchoscopy demonstrated a chronic inflammatory infiltrate with no evidence of active infection. Immunofluorescence and culture for pneumocystis, viruses and bacteria were negative. Prior to the results of bronchoscopy she was administered high-dose methylprednisolone (1 g/day) for 3 days which resulted in a dramatic resolution of all symptoms and signs. Her CXR normalised and she was discharged after 4 days. She was continued on oral prednisolone (75 mg/day) for 2 weeks, which was then weaned over a 2 week period. Because of her life-threatening interstitial pneumonitis, no further HDT was attempted. She remained well for the next 9 months on monthly pamidronate infusions.
Case 2
A 48-year-old female non-smoker was initially diagnosed with a 12 mm grade two infiltrating ductal cancer of the left breast, underwent partial mastectomy and received no adjuvant treatment. Six years later she developed disease in a left infrapectoral lymph node and received 50 Gy of RT to the left supraclavicular fossa and apex. Within 3 months she developed multiple bony metastases and was commenced on monthly goseralin acetate injections. Six months later she presented with extensive liver metastases and received three cycles of adriamycin and cyclophosphamide, but progressed on this.
She subsequently entered the same trial as the first case, receiving mobilisation chemotherapy with the same regi- men. 6 She then received the same HDT. 5 On day 4 she developed febrile neutropenia, dyspnoea and dry cough, and CXR demonstrated patchy right lower lobe consolidation and a ventilation-perfusion scan showed a matched defect in the same location. Cultures were negative and she was initially treated with intravenous gentamicin and tazocin. However, she had persistent fever despite recovery of her neutrophil count by day 11. Her antibiotics were changed to meropenem and ciprofloxacin without resolution of fever or hypoxia. On day 13, when cultures remained negative, she was commenced on prednisolone at a dose of 75 mg/day with prompt resolution of her fever and clinical improvement, allowing her to be discharged. Her steroids were gradually weaned until the time she was readmitted for her second cycle of high-dose chemotherapy.
On the first day of HDT, after she had received CTX (4 g/m 2 ) and TT (115 mg/m 2 ), she developed a high fever and was commenced on dexamethasone intravenously 8 mg four times a day. Her fever promptly settled and a full septic work-up was negative for evidence of infection. She completed her HDT conditioning regimen, her dexame- thasone was weaned to 4 mg twice a day and she was discharged after infusion of her PBPCs. However, on day 4 she was admitted with febrile neutropenia and commenced on tazocin and gentamicin. Because of persistent fevers, vancomycin and amphotericin were subsequently added. She became progressively dyspnoeic and hypoxic despite recovery of her neutrophil count and CXR demonstrated new patchy opacities in both upper lobes (Figure 3) . A HRCT demonstrated consolidation of the left upper lobe and widespread areas of ground glass opacity. CT of her abdomen was negative for hepatosplenic candidiasis. A bronchoscopy was negative for infection including pneumocystis, fungi and viruses. Bronchial washings showed nonspecific inflammatory changes.
She was commenced on high-dose methylprednisolone (1 g/day) for 3 days with dramatic clinical improvement (Figure 4 ). Given the toxicity that had complicated her treatment, a decision was made not to proceed with any further high-dose chemotherapy. She remained well without evidence of progressive disease for the next 6 months.
Discussion
Interstitial pneumonitis has been described rarely following CTX 7 and docetaxel 8 when administered alone. No literature reports to date have linked the use of thiotepa alone with interstitial pneumonitis. Lin et al 9 searched the records of the Spontaneous Reporting System (SRS) at the US Food and Drug Administration (FDA). From 1969 to 1997 there were no reports of interstitial pneumonitis linked to the use of thiotepa alone. However, there were three cases of interstitial pneumonia related to combination regimens containing both cyclophosphamide and thiotepa. Indeed, the combination of high-dose TT and CTX has been used Bone Marrow Transplantation extensively as part of preparative regimens prior to autologous or allogeneic transplantation, but to date the reported incidence of interstitial pneumonitis is relatively low.
A case similar to ours of interstitial pneumonitis has been described by Mahendra et al 10 ) and described five patients with microbiologically negative fever and diffuse pulmonary infiltrates after hematopoietic recovery, one of which required admission to intensive care. As in our report, four patients received methylprednisolone at a dose of 1 mg/kg with rapid resolution of fever and pulmonary findings.
Indeed, it may be that it is the combination of the drugs we used that was responsible for the development of the interstitial pneumonitis. Of note in both cases reported here, co-existent infection was excluded and bronchoscopy demonstrated findings consistent with drug-induced pneumonitis. Of interest, both patients had previously received radiotherapy involving the lungs, albeit with limited lung exposure. Our centre has recently reported two trials of high-dose chemotherapy with stem cell support for metastatic breast cancer. 5, 13 In the first study 13 ). In this study two patients developed reversible grade 2 interstitial pneumonitis which responded to oral steroid treatment.
It is possible that the docetaxel substitution for paclitaxel in our subsequent study may have contributed to the development of interstitial pneumonitis. 5 In this study, in which both patients reported here took part, we have noted an additional two patients who developed IP. One patient received CTX (4 g/m we have observed high fever with hypotension and hypoxia shortly after completing the first day of high-dose chemotherapy (CTX and TT). All patients were treated with oral prednisolone (75 mg/day) with prompt resolution of fever. All patients completed administration of the HDT regimen and none of these patients went on to develop life-threatening pneumonitis (as was seen with the use of docetaxel) and all were able to complete three cycles of high-dose chemotherapy with peripheral blood stem cell rescue.
The way in which chemotherapy causes lung damage is unclear. Various mechanisms have been proposed. For example, chemotherapy may induce immunomodulation that indirectly contributes to lung injury. In two cases of docetaxel-associated interstitial pulmonary injury described by Merad et al, 8 the two patients, with adenocarcinoma of the lung, also had a marked anti-tumor effect from the drug. The authors postulated that docetaxel may have caused the proliferation of cytotoxic T cells against a specific pulmonary antigen expressed by the tumor.
Alternatively chemotherapy may result in direct lung damage by the production of reactive oxygen metabolites such as nitric oxide. Transforming growth factor beta (TGF ␤) is thought to play a role in stimulation of fibrosis in the lung. TGF ␤ is a pleotropic cytokine that can down-regulate nitric oxide production, as well as up-regulate collagen expression.
14 Anscher et al 15 found a strong correlation between high serum levels of TGF ␤ measured after induction chemotherapy, and the subsequent development of pulmonary fibrosis and hepatic veno-occlusive disease after high-dose chemotherapy and autologous bone marrow transplantation. Elevated TGF ␤ levels, in response to the production of reactive oxygen metabolites, may play a role in the production of chemotherapy-related interstitial pneumonitis.
We have demonstrated that severe interstitial pneumonitis can occur following a high-dose CTX, TT, docetaxel combination. Based on our experience and previous reports we believe the major drugs implicated in the pathogenesis of the IP are the CTX and TT. Nonetheless, we have only seen life-threatening IP when docetaxel was added to this combination at a slightly higher dose than is commonly administered (125 mg/m 2 ) and it is possible that the addition of this drug predisposes to the severity of the IP.
With a high clinical suspicion, this rapidly progressive life-threatening complication can be recognized early and effectively treated with steroids. The most severe form seems to occur following hemopoietic recovery with the hallmarks of high fever, dyspnoea and pulmonary infiltrates, sometimes only visible on HRCT, with a dramatic response to high-dose methylprednisolone. 
